KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBITDA (2016 - 2025)

Historic EBITDA for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $259.3 million.

  • Alnylam Pharmaceuticals' EBITDA rose 35477.94% to $259.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.6 million, marking a year-over-year increase of 11435.44%. This contributed to the annual value of -$289.3 million for FY2024, which is 3094.86% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported EBITDA of $259.3 million as of Q3 2025, which was up 35477.94% from -$58.7 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year EBITDA high stood at $259.3 million for Q3 2025, and its period low was -$407.5 million during Q3 2022.
  • For the 5-year period, Alnylam Pharmaceuticals' EBITDA averaged around -$134.4 million, with its median value being -$168.6 million (2023).
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' EBITDA tumbled by 16672.98% in 2024, and later surged by 35477.94% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' EBITDA (Quarter) stood at -$257.5 million in 2021, then grew by 19.08% to -$208.4 million in 2022, then surged by 38.13% to -$128.9 million in 2023, then rose by 27.5% to -$93.5 million in 2024, then skyrocketed by 377.42% to $259.3 million in 2025.
  • Its EBITDA was $259.3 million in Q3 2025, compared to -$58.7 million in Q2 2025 and -$60.5 million in Q1 2025.